Two cases with de novo 3q26.31 microdeletion suggest a role for FNDC3B in human craniofacial development.

Here, we report strong evidence for a role of the FNDC3B gene in craniofacial development. Chromosomal microarray identified deletions at 3q26.31 in two patients with dysmorphic facial features. Parental FISH studies demonstrated that they are de novo; therefore, these two 3q26.31 microdeletions likely contribute to the patients' dysmorphic features. Interestingly, the minimal region of overlap contains only the FNDC3B gene. Ffibronectin domain III-containing protein 3B (FNDC3B), also known as factor for adipocyte differentiation-104 (FAD104), was first identified as a positive regulator of adipogenesis in a mouse model. Excitingly, further studies in a mouse model have recently demonstrated that FNDC3B is required for normal calvarial bone formation and negatively regulated calvarial cell differentiation through inhibition of BMP/Smad signaling. fndc3b-deficient mice have multiple cranial and skeletal malformations, such as craniosynostosis-like premature calvarial ossification, and skeletal deformities in the anterior fontanel and femurs. In summary, we report the first two patients with de novo 3q26.31 microdeletions. Both have dysmorphic features, consistent with the phenotypes seen in fndc3b-deficient mice in animal studies, which imply a critical role of FNDC3B in human craniofacial development. © 2016 Wiley Periodicals, Inc.

Rare exonic deletions implicate the synaptic organizer Gephyrin (GPHN) in risk for autism, schizophrenia and seizures.

The GPHN gene codes for gephyrin, a key scaffolding protein in the neuronal postsynaptic membrane, responsible for the clustering and localization of glycine and GABA receptors at inhibitory synapses. Gephyrin has well-established functional links with several synaptic proteins that have been implicated in genetic risk for neurodevelopmental disorders such as autism spectrum disorder (ASD), schizophrenia and epilepsy including the neuroligins (NLGN2, NLGN4), the neurexins (NRXN1, NRXN2, NRXN3) and collybistin (ARHGEF9). Moreover, temporal lobe epilepsy has been linked to abnormally spliced GPHN mRNA lacking exons encoding the G-domain of the gephyrin protein, potentially arising due to cellular stress associated with epileptogenesis such as temperature and alkalosis. Here, we present clinical and genomic characterization of six unrelated subjects, with a range of neurodevelopmental diagnoses including ASD, schizophrenia or seizures, who possess rare de novo or inherited hemizygous microdeletions overlapping exons of GPHN at chromosome 14q23.3. The region of common overlap across the deletions encompasses exons 3-5, corresponding to the G-domain of the gephyrin protein. These findings, together with previous reports of homozygous GPHN mutations in connection with autosomal recessive molybdenum cofactor deficiency, will aid in clinical genetic interpretation of the GPHN mutation spectrum. Our data also add to the accumulating evidence implicating neuronal synaptic gene products as key molecular factors underlying the etiologies of a diverse range of neurodevelopmental conditions.

Ready reference to common segmental aneusomies by syndromic names, major features and chromosomal locations.

Abnormal gene dosage usually results in recognizable phenotypic abnormalities, especially if it involves a series of contiguous genes. Schmickel (1986) defined contiguous gene syndromes as diseases resulting from loss or gain of a series of adjacent genes. The terms microdeletion and microduplication as well as segmental aneusomy have also been used to describe such losses or gains that may not be readily detectable by Gbanded analysis. The loss (haploinsufficiency) or gain of a series of adjoining genes may result in a direct phenotypic effect and/or cause a genetic regulatory disturbance. Such syndromic gains or losses are often detectable when in situ hybridization of fluorescent labeled DNA probes or array comparative genomic hybridization technique are used (Gersen and Keagle 2005; Stumm et al. 1999; Barch, Knutsen and Spurbeck 1997). Segmental aneusomies generally occur due to homologous pairing between non-allelic low copy repeats (LCR) followed by crossing over. The LCRs, as part of the repetitive DNA sequences range from 1-500 Kb repeats, share >97% base sequence identity and constitute up to five percent of the genomic DNA. They are distributed throughout the genome, but are more concentrated near the centromeres and telomeres. A segment of 300 bp completely identical sequence within the LCRs is adequate for mediating non-allelic homologous or paralogous pairing. This process results in generating both deletion and duplication of a defined segment.